A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia

Supportive Care in Cancer

Volumn 12, Issue 10, 2004, Pages 725-730

  Lalami, Y ^a   Paesmans, M ^a   Aoun, M ^a   Munoz Bermeo, R ^a   Reuss, K ^a   Cherifi, S ^b   Alexopoulos, C G ^c   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Febrile neutropenia; G CSF; Secondary prevention

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CEFTRIAXONE; CIPROFLOXACIN; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MACROLIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNINDEXED DRUG; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SCREENING; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEADACHE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SECONDARY PREVENTION; SOLID TUMOR; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 5444230522     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0658-6     Document Type: Article

References (24)

1. Bodey GP, Buckley M, Sathe Y et al (1966) Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-339
2. Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocyte-macrophage-stimulating factors in febrile neutropenic cancer patients: systematic review of the literature with meta-analysis. Support. Care Cancer 10:181-188
3. Blay JY, Chauvin F, Le Cesne B et al (1996) Early lymphopenia after cytotoxic chemotherapy as risk factor for febrile neutropenia. J Clin Oncol 14:636-643
4. Chang J (2000) Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36:S11-S14
5. Chouaid C, Bassinet L, Fuhrman C et al (1998) Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small cell lung cancer: an analysis using a markov model. J Clin Oncol 16:2700-2707
6. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med 325:164-170
7. Croockewit AJ, Bronchuld MH, Aapro MS et al (1997) A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Eur J Cancer 33:1732-1746
8. Cruciani M, Rampazzo R, Malena M et al(1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795-805
9. Dale DC, Liles CW, Summer WR et al 1995) Review: granulocyte colony stimulating factor. Role and relationships in infectious diseases. J Infect Dis 172:1061-1075
10. Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179-1187
11. Groopman JE, Molina JM, Scadden DT (1989) Hematopoietic growth factors. Biology and clinical applications. New Engl J Med 321:1449-1459
12. Kern WV, Cometta A, De Bock R et al (1999) for the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New Engl J Med 341:312-318
13. Klastersky J (1998) Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness. Current Opinion Oncol 10:284-290
14. Lyman GH(2000) A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Eur J Cancer 36:S15-S21
15. Lyman GH, Kuderer N, Greene J et al (1998) The economics of febrile neutropenia: implications of the use of colony-stimulating factors. Eur J Cancer 34:1857-1864
16. Messori A, Trippoli S, Tendi E (1996) G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 21:57-63
17. Mitchell P, Morland B, Stevens M et al (1997) Granulocyte colony-stimulating factor in established febrile neutropenia: a randomised study of paediatric patients. J Clin Oncol 15:1163-1170
18. Ozer H, Armitage JO, Bennett CL et al (2000) 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585
19. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 328:1323-1332
20. Schneider CM, Daschner FD (1998) Colony-stimulating factors and antibiotics - a new prospect in treating infectious diseases? Clin Microbiol Infect 4:119-122
21. Silber JH, Fridman M, Robert S et al (1998) First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early-stage breast cancer therapy. J Clin Oncol 16:2392-2400
22. Tjan-Heijnen VCG, Postmus PE, Ardizzoni A et al (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359-1368
23. Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324
24. Wood WC, Budman D, Korzun A et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 330:1253-1259